The US FDA approved Eli Lilly's Zepbound as the first ever medication for obstructive sleep apnea for patients who also have ...

Lilly’s Zepbound has become the first prescription medicine approved to treat adults with moderate to severe obstructive sleep apnoea (OSA) and obesity.

The U.S. Food and Drug Administration (FDA) has approved the first prescription medication specifically for treating o ...

Lilly and Novo still dominate the market for weight-loss and diabetes drugs, but the race is heating up in more ways than one ...

The drug helped patients reduce their weight by only 22.7 per cent, falling short of the anticipated result. Novo’s shares ...

The U.S. Food and Drug Administration on Friday approved the first prescription medicine for obstructive sleep apnea: the ...

In a recent head-to-head study involving Novo Nordisk 's Wegovy, Zepbound came out on top, resulting in average weight loss ...

Already established as cornerstone therapies in diabetes and obesity, GLP-1 receptor agonists have now cracked into the ...

Unless you’ve been living under a rock, you know that weight-loss drugs are the talk of the town. GLP-1 drugs, in particular, ...

Zepbound, a popular weight loss drug, has become the first FDA-approved prescription medication to treat obstructive sleep ...

Eli Lilly's Zepbound has become the first drug to be FDA-approved for obstructive sleep apnoea (OSA), a sleep-related ...

Novo Nordisk and Eli Lilly are currently a duopoly in the obesity market, which reached a value of $24 billion last year ...